Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Preexisting vs. de novo antibodies against SARS-CoV-2 in individuals without or with virus infection: impact on antibody therapy, vaccine research and serological testing

Abstract The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology, epidemiology, drug development, and vaccine research. Recent studies reported that s...

Full description

Bibliographic Details
Main Authors: Kar Muthumani, Ziyang Xu, Moonsup Jeong, Joel N. Maslow, Vaniambadi S. Kalyanaraman, Alagarsamy Srinivasan
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Translational Medicine Communications
Online Access:https://doi.org/10.1186/s41231-021-00093-2

Internet

https://doi.org/10.1186/s41231-021-00093-2

Similar Items